Developer docs
API playgroundTry for free, no card

Search company profiles

PDS Biotechnology

Full company profile

uuid0004pn5

Namestring
PDS Biotechnology
Legal namestring
PDS Biotechnology Corporation
Websiteurl
pdsbiotech.com
Company typeenum
Public
Founded yearint
2019
Descriptiontext

PDS Biotechnology Corporation (NASDAQ: PDSB) is a clinical-stage biopharmaceutical company headquartered in Princeton, New Jersey that develops targeted cancer immunotherapies and infectious disease vaccines based on two proprietary T-cell activating platforms, Versamune® and Infectimune™. The Versamune® platform is designed to deliver disease-specific antigens for in vivo uptake and processing while activating the type 1 interferon immunological pathway, generating potent tumor-specific CD4+ and CD8+ killer T cells independent of patient HLA background. The company's lead oncology candidate, PDS0101 (Versamune® HPV), targets HPV16-positive cancers—principally recurrent/metastatic head and neck squamous cell carcinoma—where Phase 2 (VERSATILE-002) data reported median overall survival of 39.3 months, disease control rate of 77.4%, and 21% of patients with 90–100% tumor shrinkage. Additional pipeline assets include PDS01ADC, a tumor-targeted IL-12 immunocytokine that uses the NHS76 antibody to bind DNA exposed in tumor cell death; PDS0102 (Versamune®-TARP) for prostate, breast and AML; PDS0103 (Versamune®-MUC1) for breast, colon, lung and ovarian cancers; and PDS0202, an Infectimune™-based universal influenza vaccine leveraging COBRA antigens licensed from the University of Georgia.\n\nThe company's competitive position rests on the combination of these two platform assets—using Versamune® for T-cell priming alongside PDS01ADC's targeted IL-12 delivery to the tumor microenvironment—intended to generate a potent tumor-specific T-cell attack while suppressing the tumor's immune defenses. Notable clinical signals include a 77.8% objective response rate in metastatic colorectal cancer patients treated with PDS01ADC versus approximately 35% in a parallel cohort, a >80% two-year survival rate in the mCRC PDS01ADC cohort, a 100% 36-month survival rate in MD Anderson IMMUNOCERV cervical cancer patients completing 5/5 doses, and a 75% 36-month survival rate in ICI-naïve HPV16-positive patients (versus a published median OS of 7–11 months). PDS0101 has received FDA Fast Track Designation, US Patent 15,724,818 extends protection to October 2037, and newly granted composition-of-matter patents (including a 2026 Japanese patent) extend exclusivity into the 2040s.\n\nAs a clinical-stage company with no approved or commercial products, PDS Biotech is pre-revenue and funds operations through public equity offerings, a $35 million Horizon Technology Finance debt facility, and registered direct offerings. The company has not yet built a commercial sales organization but has assembled an academic and industry collaboration network—most notably a Merck agreement to combine PDS0101 with KEYTRUDA® (pembrolizumab), plus investigator-initiated and NCI-led Phase 2 trials at MD Anderson Cancer Center, Mayo Clinic, University of North Carolina Lineberger, the National Cancer Institute, and the National Institute of Allergy and Infectious Diseases. Upon potential FDA approval of PDS0101, the company would commercialize to U.S. and European oncologists treating HPV16-positive head and neck cancer patients, likely through specialty pharmacy/oncology sales channels and leveraging the existing Merck relationship for combination therapy positioning.

Short descriptiontext

PDS Biotechnology is a clinical-stage biopharmaceutical company developing targeted cancer immunotherapies and infectious disease vaccines using its proprietary Versamune® and Infectimune™ T-cell activating platforms, with lead candidate PDS0101 now in Phase 3 for HPV16-positive head and neck cancer.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersPrinceton, United States
HQ citystring
Princeton
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
cancer immunotherapy, T cell activating platform, infectious disease vaccines, HPV16-positive cancer treatment, tumor-targeted immunocytokines
Industry3 codes
PRIMARYHLAAAEAB
Therapeutic Vaccines (cancer, chronic infection immunotherapy)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
SECONDARYHLAAAAAE
Antibody-Drug Conjugates (ADCs) & Antibody Conjugates
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAIAEAG
Therapeutic Vaccines (e.g., Cancer/Chronic Infection)
NAICS code3 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Pharmaceutical Preparation Manufacturing325412
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Pharmaceutical Preparations2834
Product category
Cancer Immunotherapy
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Pharmaceutical Product Sales
TypeOne Time License
Description

Pre-revenue clinical-stage biotech company. Expected to generate revenue through sales of proprietary immunotherapy drugs upon FDA approval, starting with PDS0101 for HPV16-positive head and neck cancer

pdsbiotech.com
2Licensing Royalties
TypeLicensing Royalties
Description

May pursue licensing arrangements for Versamune® and Infectimune™ platforms to other pharmaceutical companies

biospace.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

PDS Biotechnology develops clinical-stage immunotherapy product candidates for cancer and infectious diseases using its proprietary Versamune® and Infectimune™ T-cell activating platforms. Its lead candidate PDS0101 targets HPV16-positive head and neck and other HPV-related cancers in combination with checkpoint inhibitors, and additional candidates (PDS01ADC, PDS0102, PDS0103, PDS0301, PDS0202) target solid tumors and influenza. The company is pre-revenue and is advancing PDS0101 through a Phase 3 trial (VERSATILE-003) toward potential FDA accelerated approval.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 7 values shown
  • 77.8% objective response rate in metastatic colorectal cancer patients with PDS01ADC vs 35% in parallel trial without PDS01ADC
+6 more records
Product overview1 text field

PDS Biotechnology is a late-stage immunotherapy company developing a pipeline of targeted cancer immunotherapies and infectious disease vaccines based on proprietary Versamune® and Infectimune™ T cell activating platforms. The core product portfolio includes lead candidate PDS0101 (Versamune® HPV) for HPV16-positive cancers, PDS01ADC tumor-targeted IL-12 immunocytokine, and pipeline candidates PDS0102, PDS0103, and PDS0202 for various cancers and infectious diseases. The Versamune® platform enables in vivo delivery of disease-specific antigens and activation of type 1 interferon pathway, while Infectimune™ provides robust antibody and T cell responses for vaccine applications.

Product and service6 records
1PDS0101 (Versamune® HPV)
CategoryOncology immunotherapy candidate
Description

Novel HPV-targeted immunotherapy combining Versamune® technology with HPV16 protein fragments to induce potent killer T cells that recognize and attack HPV16-positive cancers (head and neck, cervical, anal, penile, vaginal, vulvar); administered by subcutaneous injection alone or with checkpoint inhibitors.

2PDS01ADC
CategoryOncology immunotherapy candidate / immunocytokine
Description

Tumor-targeted IL-12 immunocytokine that uses the NHS76 antibody to bind DNA exposed in areas of tumor cell death, delivering IL-12 directly to the tumor while minimizing systemic exposure. In trials for metastatic colorectal cancer (MSS/pMMR), metastatic castration-resistant prostate cancer, and other solid tumors.

3PDS0102 (Versamune®-TARP)
CategoryPipeline oncology immunotherapy candidate
Description

Versamune®-based immunotherapy combined with TARP antigen targeting prostate cancer, breast cancer, and acute myeloid leukemia (AML).

4PDS0103 (Versamune®-MUC1)
CategoryPipeline oncology immunotherapy candidate
Description

Versamune®-based immunotherapy combined with MUC1 antigen targeting multiple cancers including breast, colon, lung, and ovarian cancers.

5PDS0202 (Infectimune™ Universal Flu Vaccine)
CategoryInfectious disease vaccine candidate
Description

Universal influenza vaccine combining the proprietary Infectimune™ platform with COBRA (Computationally Optimized Broadly Reactive Antigens) licensed from the University of Georgia, designed to provide broad protection against multiple flu strains.

6PDS0301
CategoryPipeline oncology immunotherapy candidate
Description

Novel investigational tumor-targeting IL-12 antibody-drug conjugate that enhances the proliferation, potency, and longevity of T cells in the tumor microenvironment.

Scale indicator12 records

Each record includes

Type, Value, Description, Source

Partnership8 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-10-03
Description

Leads IMMUNOCERV Phase 2 clinical trial in first-line treatment of locally advanced cervical cancer with PDS0101. Reported 100% 36-month survival rate in patients who received 5/5 doses of Versamune® HPV.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-02-15
Description

Investigator-Initiated Trial MC200710 evaluating PDS0101 alone or in combination with KEYTRUDA® in patients with HPV-associated oropharyngeal cancer at high risk of recurrence. Led by Drs. Routman, Price, Van Abel, and Chintakuntlawar.

3National Institute of Allergy and Infectious Diseases (NIAID)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-01-27
Description

NIAID-sponsored preclinical work for PDS0202 universal influenza vaccine performed by Dr. Jerold Woodward at University of Kentucky and Dr. Ted Ross at University of Georgia.

pdsbiotech.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-11-08
Description

Licensed protein from NCI for treatment of acute myeloid leukemia, prostate and breast cancers. NCI conducts multiple Phase 2 clinical trials evaluating PDS0101 and PDS01ADC across various cancer indications.

5University of Georgia
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2021-11-01
Description

Licensed COBRA (Computationally Optimized Broadly Reactive Antigens) antigens designed by Dr. Ted Ross for development of universal influenza vaccine PDS0202. Dr. Ross serves as Principal Investigator at NIAID Collaborative Influenza Vaccine Innovation Center.

pdsbiotech.com
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2021-05-27
Description

Strategic partnership to support awareness and education around head and neck cancers and HPV16-positive cancer treatments.

7Farmacore / Blanver Consortium
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2021-02-22
Description

Partnership with Farmacore and Brazilian-based Blanver to commercialize Versamune®-based T-cell inducing COVID-19 vaccine candidate. Blanver brings pharmaceutical manufacturing and commercialization expertise in Brazil.

pdsbiotech.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2020-03-01
Description

Collaboration to evaluate PDS0101 in combination with KEYTRUDA® (pembrolizumab) in Phase 2 VERSATILE-002 trial for recurrent or metastatic HPV16-positive head and neck cancer. Partnership facilitates access to Merck's anti-PD-1 therapy for combination treatment.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
1Bristol-Myers Squibb
TypeBroad incumbent
Description

Bristol-Myers Squibb is a broad immuno-oncology incumbent with Opdivo, Yervoy, and a growing ADC and bispecific pipeline that overlaps with the HPV+ head and neck, mCRC, and prostate cancer indications PDS Biotech is pursuing.

TypeDirect peer
Description

Immatics develops TCR-based immunotherapies (ACTengine®, ACTallo®, TCER®) targeting tumor-specific antigens. It is a direct peer in the field of antigen-specific T-cell activating cancer therapies and shares the immunotherapy + checkpoint-inhibitor combination strategy with PDS Biotech.

TypeDirect peer
Description

Moderna is developing mRNA-based personalized and off-the-shelf cancer vaccines (e.g., mRNA-4157/V940 with Merck) — the most direct competitor in the therapeutic cancer vaccine space, and a peer to PDS Biotech's Versamune®-based HPV16 vaccine franchise.

4Heat Biologics
TypeDirect peer
Description

Heat Biologics is a small clinical-stage cancer vaccine company developing T-cell activating immunotherapies (e.g., HS-110, PTX-35) — a closely comparable peer in size, stage, and mechanism to PDS Biotech.

TypeDirect peer
Description

Adaptimmune develops SPEAR T-cell receptor therapies (e.g., afami-cel, Tecelra) for solid tumors, sharing with PDS Biotech the focus on antigen-specific T-cell activation in solid tumor indications.

TypeDirect peer
Description

Gritstone develops neoantigen-based cancer vaccines (GRANITE, SLATE) using a viral vector prime + self-amplifying RNA boost to drive tumor-specific T-cell responses, an approach directly comparable to PDS Biotech's Versamune® platform.

TypeDirect peer
Description

Marker Therapeutics is a small clinical-stage company developing multi-tumor-associated antigen (TAA)-specific T-cell therapies, a directly comparable approach to PDS Biotech's antigen-directed T-cell platform.

TypeDirect peer
Description

BioNTech's oncology pipeline (BNT122/RO7198457, FixVac, individualized mRNA cancer vaccines) directly competes in the antigen-specific T-cell activating cancer vaccine category that PDS Biotech targets with PDS0101.

TypeBroad incumbent
Description

Merck is both PDS Biotech's combination partner (supplying KEYTRUDA® for PDS0101 trials) and a broad incumbent in immuno-oncology with PD-1, ADC, and other franchises that compete with the same indications PDS Biotech is targeting.

10Hookipa Pharma
TypeDirect peer
Description

Hookipa is a clinical-stage biotech using arenavirus-based platforms (TheraT®, VaxWave®) to induce potent CD8+ T-cell responses against infectious disease and cancer targets — closely comparable to PDS Biotech's Versamune® and Infectimune™ platforms.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles10 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds8 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

PDS Biotechnology

Cancer Immunotherapypdsbiotech.com

PDS Biotechnology is a clinical-stage biopharmaceutical company developing targeted cancer immunotherapies and infectious disease vaccines using its proprietary Versamune® and Infectimune™ T-cell activating platforms, with lead candidate PDS0101 now in Phase 3 for HPV16-positive head and neck cancer.

What PDS Biotechnology does

PDS Biotechnology Corporation (NASDAQ: PDSB) is a clinical-stage biopharmaceutical company headquartered in Princeton, New Jersey that develops targeted cancer immunotherapies and infectious disease vaccines based on two proprietary T-cell activating platforms, Versamune® and Infectimune™. The Versamune® platform is designed to deliver disease-specific antigens for in vivo uptake and processing while activating the type 1 interferon immunological pathway, generating potent tumor-specific CD4+ and CD8+ killer T cells independent of patient HLA background. The company's lead oncology candidate, PDS0101 (Versamune® HPV), targets HPV16-positive cancers—principally recurrent/metastatic head and neck squamous cell carcinoma—where Phase 2 (VERSATILE-002) data reported median overall survival of 39.3 months, disease control rate of 77.4%, and 21% of patients with 90–100% tumor shrinkage. Additional pipeline assets include PDS01ADC, a tumor-targeted IL-12 immunocytokine that uses the NHS76 antibody to bind DNA exposed in tumor cell death; PDS0102 (Versamune®-TARP) for prostate, breast and AML; PDS0103 (Versamune®-MUC1) for breast, colon, lung and ovarian cancers; and PDS0202, an Infectimune™-based universal influenza vaccine leveraging COBRA antigens licensed from the University of Georgia.\n\nThe company's competitive position rests on the combination of these two platform assets—using Versamune® for T-cell priming alongside PDS01ADC's targeted IL-12 delivery to the tumor microenvironment—intended to generate a potent tumor-specific T-cell attack while suppressing the tumor's immune defenses. Notable clinical signals include a 77.8% objective response rate in metastatic colorectal cancer patients treated with PDS01ADC versus approximately 35% in a parallel cohort, a >80% two-year survival rate in the mCRC PDS01ADC cohort, a 100% 36-month survival rate in MD Anderson IMMUNOCERV cervical cancer patients completing 5/5 doses, and a 75% 36-month survival rate in ICI-naïve HPV16-positive patients (versus a published median OS of 7–11 months). PDS0101 has received FDA Fast Track Designation, US Patent 15,724,818 extends protection to October 2037, and newly granted composition-of-matter patents (including a 2026 Japanese patent) extend exclusivity into the 2040s.\n\nAs a clinical-stage company with no approved or commercial products, PDS Biotech is pre-revenue and funds operations through public equity offerings, a $35 million Horizon Technology Finance debt facility, and registered direct offerings. The company has not yet built a commercial sales organization but has assembled an academic and industry collaboration network—most notably a Merck agreement to combine PDS0101 with KEYTRUDA® (pembrolizumab), plus investigator-initiated and NCI-led Phase 2 trials at MD Anderson Cancer Center, Mayo Clinic, University of North Carolina Lineberger, the National Cancer Institute, and the National Institute of Allergy and Infectious Diseases. Upon potential FDA approval of PDS0101, the company would commercialize to U.S. and European oncologists treating HPV16-positive head and neck cancer patients, likely through specialty pharmacy/oncology sales channels and leveraging the existing Merck relationship for combination therapy positioning.

PDS Biotechnology firmographics

Firmographics
Name
PDS Biotechnology
Legal name
PDS Biotechnology Corporation
Website
https://pdsbiotech.com
Company type
Public
Founded year
2019
Operating status
Operating
Headcount range
11–50 employees
Short description
PDS Biotechnology is a clinical-stage biopharmaceutical company developing targeted cancer immunotherapies and infectious disease vaccines using its proprietary Versamune® and Infectimune™ T-cell activating platforms, with lead candidate PDS0101 now in Phase 3 for HPV16-positive head and neck cancer.
Ownership category
akta.pro rank

PDS Biotechnology industry classification

Industry
Product category
Cancer Immunotherapy
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAAAEAB
Therapeutic Vaccines (cancer, chronic infection immunotherapy)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
SECONDARYHLAAAAAE
Antibody-Drug Conjugates (ADCs) & Antibody Conjugates
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAIAEAG
Therapeutic Vaccines (e.g., Cancer/Chronic Infection)

Keywords

  • Cancer immunotherapy
  • T cell activating platform
  • Infectious disease vaccines
  • HPV16-positive cancer treatment
  • Tumor-targeted immunocytokines

Where PDS Biotechnology is headquartered

Location

Headquarters

HQ city
Princeton
HQ country
United States
HQ region
North America

Offices2 records

Markets served

PDS Biotechnology business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

  1. Pharmaceutical Product Sales: Pre-revenue clinical-stage biotech company. Expected to generate revenue through sales of proprietary immunotherapy drugs upon FDA approval, starting with PDS0101 for HPV16-positive head and neck cancer
  2. Licensing Royalties: May pursue licensing arrangements for Versamune® and Infectimune™ platforms to other pharmaceutical companies

Go-to-market motion1 record

Distribution channels2 records

Marketing channels5 records

PDS Biotechnology product offering

Product offering

Core offering

PDS Biotechnology develops clinical-stage immunotherapy product candidates for cancer and infectious diseases using its proprietary Versamune® and Infectimune™ T-cell activating platforms. Its lead candidate PDS0101 targets HPV16-positive head and neck and other HPV-related cancers in combination with checkpoint inhibitors, and additional candidates (PDS01ADC, PDS0102, PDS0103, PDS0301, PDS0202) target solid tumors and influenza. The company is pre-revenue and is advancing PDS0101 through a Phase 3 trial (VERSATILE-003) toward potential FDA accelerated approval.

Product overview

PDS Biotechnology is a late-stage immunotherapy company developing a pipeline of targeted cancer immunotherapies and infectious disease vaccines based on proprietary Versamune® and Infectimune™ T cell activating platforms. The core product portfolio includes lead candidate PDS0101 (Versamune® HPV) for HPV16-positive cancers, PDS01ADC tumor-targeted IL-12 immunocytokine, and pipeline candidates PDS0102, PDS0103, and PDS0202 for various cancers and infectious diseases. The Versamune® platform enables in vivo delivery of disease-specific antigens and activation of type 1 interferon pathway, while Infectimune™ provides robust antibody and T cell responses for vaccine applications.

Differentiator

Problem solved

Functional benefit

Products and services

  • PDS0101 (Versamune® HPV) Novel HPV-targeted immunotherapy combining Versamune® technology with HPV16 protein fragments to induce potent killer T cells that recognize and attack HPV16-positive cancers (head and neck, cervical, anal, penile, vaginal, vulvar); administered by subcutaneous injection alone or with checkpoint inhibitors.
  • PDS01ADC Tumor-targeted IL-12 immunocytokine that uses the NHS76 antibody to bind DNA exposed in areas of tumor cell death, delivering IL-12 directly to the tumor while minimizing systemic exposure. In trials for metastatic colorectal cancer (MSS/pMMR), metastatic castration-resistant prostate cancer, and other solid tumors.
  • PDS0102 (Versamune®-TARP) Versamune®-based immunotherapy combined with TARP antigen targeting prostate cancer, breast cancer, and acute myeloid leukemia (AML).
  • PDS0103 (Versamune®-MUC1) Versamune®-based immunotherapy combined with MUC1 antigen targeting multiple cancers including breast, colon, lung, and ovarian cancers.
  • PDS0202 (Infectimune™ Universal Flu Vaccine) Universal influenza vaccine combining the proprietary Infectimune™ platform with COBRA (Computationally Optimized Broadly Reactive Antigens) licensed from the University of Georgia, designed to provide broad protection against multiple flu strains.
  • PDS0301 Novel investigational tumor-targeting IL-12 antibody-drug conjugate that enhances the proliferation, potency, and longevity of T cells in the tumor microenvironment.

Quantifiable outcome

  • 77.8% objective response rate in metastatic colorectal cancer patients with PDS01ADC vs 35% in parallel trial without PDS01ADC
  • +6 more outcomes

Companies that use PDS Biotechnology

Customer profile

Named customers4 records

Segments5 records

Ideal customer profiles2 records

PDS Biotechnology technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

PDS Biotechnology partnerships and signals

Strategic signal

Partnerships

Eight partnerships are on record, tiered core and minor.

  • University of Texas MD Anderson Cancer CentercoreStrategic or Co-development Partner · 3 October 2022Leads IMMUNOCERV Phase 2 clinical trial in first-line treatment of locally advanced cervical cancer with PDS0101. Reported 100% 36-month survival rate in patients who received 5/5 doses of Versamune® HPV.
  • Mayo CliniccoreStrategic or Co-development Partner · 15 February 2022Investigator-Initiated Trial MC200710 evaluating PDS0101 alone or in combination with KEYTRUDA® in patients with HPV-associated oropharyngeal cancer at high risk of recurrence. Led by Drs. Routman, Price, Van Abel, and Chintakuntlawar.
  • National Institute of Allergy and Infectious Diseases (NIAID)coreStrategic or Co-development Partner · 27 January 2022NIAID-sponsored preclinical work for PDS0202 universal influenza vaccine performed by Dr. Jerold Woodward at University of Kentucky and Dr. Ted Ross at University of Georgia.
  • National Cancer InstitutecoreStrategic or Co-development Partner · 8 November 2021Licensed protein from NCI for treatment of acute myeloid leukemia, prostate and breast cancers. NCI conducts multiple Phase 2 clinical trials evaluating PDS0101 and PDS01ADC across various cancer indications.
  • University of GeorgiacoreTechnology or Integration · 1 November 2021Licensed COBRA (Computationally Optimized Broadly Reactive Antigens) antigens designed by Dr. Ted Ross for development of universal influenza vaccine PDS0202. Dr. Ross serves as Principal Investigator at NIAID Collaborative Influenza Vaccine Innovation Center.
  • Head and Neck Cancer AllianceminorStrategic or Co-development Partner · 27 May 2021Strategic partnership to support awareness and education around head and neck cancers and HPV16-positive cancer treatments.
  • Farmacore / Blanver ConsortiumminorStrategic or Co-development Partner · 22 February 2021Partnership with Farmacore and Brazilian-based Blanver to commercialize Versamune®-based T-cell inducing COVID-19 vaccine candidate. Blanver brings pharmaceutical manufacturing and commercialization expertise in Brazil.
  • Merck (Merck Sharp & Dohme Corp.)coreStrategic or Co-development Partner · 1 March 2020Collaboration to evaluate PDS0101 in combination with KEYTRUDA® (pembrolizumab) in Phase 2 VERSATILE-002 trial for recurrent or metastatic HPV16-positive head and neck cancer. Partnership facilitates access to Merck's anti-PD-1 therapy for combination treatment.

Scale indicators12 records

Recent moves7 records

Expansion highlights6 records

PDS Biotechnology competitors and assessment

Company assessment

Broad incumbents

  • Bristol-Myers Squibb: Bristol-Myers Squibb is a broad immuno-oncology incumbent with Opdivo, Yervoy, and a growing ADC and bispecific pipeline that overlaps with the HPV+ head and neck, mCRC, and prostate cancer indications PDS Biotech is pursuing.
  • Merck & Co. Merck is both PDS Biotech's combination partner (supplying KEYTRUDA® for PDS0101 trials) and a broad incumbent in immuno-oncology with PD-1, ADC, and other franchises that compete with the same indications PDS Biotech is targeting.

Direct peers

  • Immatics: Immatics develops TCR-based immunotherapies (ACTengine®, ACTallo®, TCER®) targeting tumor-specific antigens. It is a direct peer in the field of antigen-specific T-cell activating cancer therapies and shares the immunotherapy + checkpoint-inhibitor combination strategy with PDS Biotech.
  • Moderna: Moderna is developing mRNA-based personalized and off-the-shelf cancer vaccines (e.g., mRNA-4157/V940 with Merck) — the most direct competitor in the therapeutic cancer vaccine space, and a peer to PDS Biotech's Versamune®-based HPV16 vaccine franchise.
  • Heat Biologics: Heat Biologics is a small clinical-stage cancer vaccine company developing T-cell activating immunotherapies (e.g., HS-110, PTX-35) — a closely comparable peer in size, stage, and mechanism to PDS Biotech.
  • Adaptimmune: Adaptimmune develops SPEAR T-cell receptor therapies (e.g., afami-cel, Tecelra) for solid tumors, sharing with PDS Biotech the focus on antigen-specific T-cell activation in solid tumor indications.
  • Gritstone bio: Gritstone develops neoantigen-based cancer vaccines (GRANITE, SLATE) using a viral vector prime + self-amplifying RNA boost to drive tumor-specific T-cell responses, an approach directly comparable to PDS Biotech's Versamune® platform.
  • Marker Therapeutics: Marker Therapeutics is a small clinical-stage company developing multi-tumor-associated antigen (TAA)-specific T-cell therapies, a directly comparable approach to PDS Biotech's antigen-directed T-cell platform.
  • BioNTech: BioNTech's oncology pipeline (BNT122/RO7198457, FixVac, individualized mRNA cancer vaccines) directly competes in the antigen-specific T-cell activating cancer vaccine category that PDS Biotech targets with PDS0101.
  • Hookipa Pharma: Hookipa is a clinical-stage biotech using arenavirus-based platforms (TheraT®, VaxWave®) to induce potent CD8+ T-cell responses against infectious disease and cancer targets — closely comparable to PDS Biotech's Versamune® and Infectimune™ platforms.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

PDS Biotechnology social profiles

Digital presence

PDS Biotechnology compliance and trust

Trust signal

Compliance1 record

PDS Biotechnology financial estimates

Financial estimate

Revenue estimate

Valuation estimate

PDS Biotechnology leadership team

Management profile

Number of profiles

Profiles10 records

PDS Biotechnology funding detail

Funding detail

Funding overview

Funding rounds8 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

PDS Biotechnology M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about PDS Biotechnology

What does PDS Biotechnology do?

PDS Biotechnology develops clinical-stage immunotherapy product candidates for cancer and infectious diseases using its proprietary Versamune® and Infectimune™ T-cell activating platforms. Its lead candidate PDS0101 targets HPV16-positive head and neck and other HPV-related cancers in combination with checkpoint inhibitors, and additional candidates (PDS01ADC, PDS0102, PDS0103, PDS0301, PDS0202) target solid tumors and influenza. The company is pre-revenue and is advancing PDS0101 through a Phase 3 trial (VERSATILE-003) toward potential FDA accelerated approval.

Is PDS Biotechnology a public or private company?

PDS Biotechnology is a public company. It is classified as public and is currently operating.

When was PDS Biotechnology founded?

PDS Biotechnology was founded in 2019. It employs 11 to 50 people.

Where is PDS Biotechnology based?

PDS Biotechnology is headquartered in Princeton, United States, in the North America region.

How does PDS Biotechnology make money?

Two revenue lines are on record. Pharmaceutical Product Sales are the primary driver. The others are licensing Royalties.

Who are PDS Biotechnology's main competitors?

Broad incumbents on record are Bristol-Myers Squibb and Merck & Co.. Direct peers are Immatics, Moderna, Heat Biologics, Adaptimmune, Gritstone bio, Marker Therapeutics, BioNTech and Hookipa Pharma.

Does PDS Biotechnology have an API?

No public API is recorded for PDS Biotechnology.

What industry is PDS Biotechnology in?

PDS Biotechnology's product category is Cancer Immunotherapy. Its primary akta.pro industry code is HLAAAEAB, Therapeutic Vaccines (cancer, chronic infection immunotherapy), with a secondary code of HLAAAAAE, Antibody-Drug Conjugates (ADCs) & Antibody Conjugates. Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
The future of tradingPDS Biotechnology Corp reports results for the quarter ended September 30 - Earnings SummaryPDS Biotechnology Corp reported a quarterly adjusted loss of 11 cents per share for the quarter ended September 30, higher than the prior year's -19 cents. Revenue was zero, and the company's shares rose 30.5% this quarter. Analysts' mean estimate was a -10-cent loss, and the average rating is 'buy' with a $4.50 price target.TradingViewPDSB: PDS0301 prioritization and PIPE financing anchor the quarter as Q3 net loss narrows YoYPDS Biotechnology Corporation reported that PDS0301 became the lead development priority, supported by an initial PIPE closing and ongoing NCI trials. Q3 net loss narrowed year-over-year, while cash and working capital declined from year-end 2025.FinancialContent Business PageGaining Ground: FNUC, PRSO, QSI, PDSB Stocks to Watch NowPeraso, Frontier Nuclear, Quantum-Si, and PDS Biotechnology reported business milestones. Peraso received a $2 million production order with shipments starting Q4 2026; Frontier Nuclear's Pine Ridge drilling aims for a resource estimate by early 2027; Quantum-Si will report Q3 results on November 5; PDS Biotechnology appointed new board members ahead of a Phase 3 trial.The future of tradingPDS Biotechnology Files Initial Beneficial Ownership Statement for Director Deborah RamsdellPDS Biotechnology director Deborah Ramsdell filed an initial beneficial ownership statement on Oct. 20, 2026. The filing was published via EDGAR, and the statement is for informational purposes only.YahooPDS Biotechnology Appoints Three Accomplished Pharma Industry Executives to Board of DirectorsPDS Biotechnology appointed John Dawson, Deborah Ramsdell, and Bruce Wendel to its board, effective October 18, 2026, following resignations of five directors. The new directors bring corporate development, commercialization, and regulatory experience, and the company plans to advance PDS0301 toward a Phase 3 trial in metastatic colorectal cancer and pursue partnerships for PDS0101.American Banking and Market NewsPDS Biotechnology Targets Phase III Trial for PDS0301 in Metastatic Colorectal CancerPDS Biotechnology plans a Phase III trial of its investigational immunocytokine PDS0301 for heavily pretreated metastatic colorectal cancer with liver metastases, following FDA discussions and NCI study data. The NCI study showed objective response rates above 70% at six months for PDS0301 versus 35% for comparator. The company expects to submit a protocol in the current quarter and target a trial start in the first quarter of 2027.Ticker ReportPDS Biotechnology Targets Phase III Trial for PDS0301 in Metastatic Colorectal CancerPDS Biotechnology plans a Phase III trial of its investigational immunocytokine PDS0301 for heavily pretreated metastatic colorectal cancer with liver metastases, following FDA discussions and NCI study data. The NCI study showed durable responses and higher objective response rates at six months for PDS0301 versus comparator. The company expects to submit a protocol in the current quarter, with a trial start targeted for the first quarter of 2027.Seeking AlphaPDS Biotechnology Corporation (PDSB) Discusses PDS-0301 Immunocytokine and Its Role in Treating Metastatic Colorectal Cancer TranscriptPDS Biotechnology held a virtual KOL event to discuss PDS-0301, an immunocytokine for metastatic colorectal cancer. The company's CEO and CMO presented, with Dr. Jonathan Hernandez detailing a Phase II study of PDS-0301 as a second-line and third-line treatment for liver metastasis.MarketBeatPDS Biotechnology Targets Phase III Trial for PDS0301 in Metastatic Colorectal CancerPDS Biotechnology plans to advance its investigational immunocytokine PDS0301 into a Phase III study for heavily pretreated metastatic colorectal cancer with liver metastases, following FDA discussions and NCI study data. The company expects to submit a protocol in the current quarter, with a trial start targeted for the first quarter of 2027.MarketBeatPDS Biotechnology Corporation (NASDAQ:PDSB) Sees Significant Decline in Short InterestPDS Biotechnology's short interest fell 56.8% to 2.77 million shares as of September 30, with institutional investors adding or reducing stakes. The stock traded at $1.60, and analysts have a consensus 'Hold' rating with a $9.00 target price.